Analytikerkommentar

Curasight: Q3 confirmed - the company is on track from a medical advancement perspective.

Curasight: Q3 confirmed - the company is on track from a medical advancement perspective

Danish based biotech company Curasight released their 3rd quarter report last week which confirmed the company is on track from a medical advancement perspective as the company continues to make progress with its so called theranostic concept to combine diagnose and treatment of various forms of cancer. Still in their developing phase, Curasight reported zero revenue and a loss before tax of DKK 8,5 million and a loss of DKK 25,3 million for the first three quarters of 2023 as the company develops its pipeline of uTRACE and uTREAT product candidates for diagnosing and treating different forms of cancer types. Cash position remains strong with a cash position of DKK 27,7 million.

Investors has grown accustomed to witnessing Curasight publish encouraging new preclinical or clinical data to support an ongoing expansion of new types of cancer forms to be diagnosed and treated. Recently, the latest example was the announcement of positive preclinical data of uTREAT for non-small cell lung cancer. What has become more interesting, however, is the announcement of partner deals that validates both uTREAT and uTRACE as concepts – but also supports the company’s funding situation. To illustrate, the share price of Curasight doubled in the weeks after the first – and so far only - of such announcements were made in the beginning of May of 2023, when Curasight entered a partnership arrangement with Curium to accelerate Curasight’s development of uTRACE for prostate cancer. Since then, Curasight has continued to develop its pipeline, but no new partnerships have been announced, and although the Curasight share price is up more than 60 percent this year making it one of the best biotech investments, investors have seen the share price drop 35 percent from its peak in May when news of the deal was released.

Investors eager to learn more about Curasight and its theranostic concept, as well as hearing more of the prospect and potential for new partnership deals can join the HCA event on Wednesday, November 29^th where CEO Ulrich Krasilnikoff and CSO and co-founder Andreas Kjær will present the 3^rd quarter report and take questions. Please sign up here: Q3 event Curasight

Disclaimer: HC Andersen Capital receives payment from Curasight for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 8:30 AM 27-11-2023.

Curasight er en dansk biotekvirksomhed med fokus på at udvikle og forbedre opdagelsen og behandlingen af kræft på en mere skånsom og effektiv måde. På nuværende tidspunkt modtager patienter radioaktiv stråling i behandlingen mod kræft. Dette skader kræftcellerne, såvel som raske celler og væv i kroppen. Curasight teknologi er baseret på formålet om ikke at skade raske celler og væv. Virksomheden har to pipeline-produkter, der begge bruger radionuklid (nuklearmedicin) til at forbedre diagnosticering og behandling af forskellige kræfttyper; uTRACE bruger den såkaldte uPAR receptore som sidder på kræftceller, som en biomarkør til at diagnosticere kræften, samt dens udvikling. Selskabets andet product uTREAT, anvender uPAR som en receptor til at behandle kræften. Baseret på stærke fase 2-data, der allerede er indsamlet i 2022, forventes Curasight at forberede fase 3 til uTRACE senere i 2022 og 2023 for følgende fire kræfttyper: prostata, hjerne, neuroendokrine og hoved- og halskræft.

Læs mere på virksomhedsside